Drugs / CX11
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07652047 | May 2026 → Mar 2027 expected | obesity disorder | Corxel Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07349381 | Mar → Jun 2026 overdue | obesity disorder, type 2 diabetes mellitus | Vincentage Pharma Co., Ltd | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07340320 | Feb → Dec 2026 expected | type 2 diabetes mellitus | Corxel Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07011797 | Jun 2025 → Mar 2026 | obesity disorder | Corxel Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07652047 ↗ |
| Known as | VCT220 | “CX11 (VCT220)” NCT07349381 ↗ |
| Route | Oral | “CX11 tablets administered orally once daily (QD) with meals” NCT07011797 ↗ |